GSK Acquires Exclusive Rights to Syndivia’s Next-Generation ADC for Advanced Prostate Cancer
GSK plc has entered into an agreement with Syndivia, a private biotechnology company specializing in next-generation antibody-drug conjugates (ADCs), granting GSK exclusive worldwide…
Read More...
Read More...
